How do I read and understand my Non-Small Cell Lung Cancer pathology report

Understanding Your NSCLC Pathology Report

A pathology report is one of the most important documents in your cancer care. It describes what the pathologist (a doctor who examines tissue under a microscope) found in your lung tissue sample. Let me walk you through what to expect and what the key sections mean.

What Your Report Should Include

According to the NCCN Guidelines for NSCLC, your pathology report should contain several critical pieces of information:

1. Histologic Type (What Kind of Lung Cancer)

This is the foundation of your diagnosis. Your report should specify which type of NSCLC you have:

• Adenocarcinoma - The most common type, usually found in the outer parts of the lung
• Squamous Cell Carcinoma - Often found in the central airways
• Large Cell Carcinoma - A less common type
• Adenosquamous Carcinoma - A mix of adenocarcinoma and squamous features

Why this matters: Different types may respond differently to treatments, so knowing your specific type helps your oncologist choose the best approach.

2. Tumor Size and Extent of Invasion

Your report should describe:

• How large the tumor is (measured in centimeters)
• How deeply it has invaded into surrounding tissue
• Whether it has invaded blood vessels or lymph vessels

What to look for: Terms like "invasion" or "penetration" describe how far the cancer has spread into healthy tissue. This information is crucial for staging (determining how advanced your cancer is).

3. Surgical Margins (If Surgery Was Performed)

If you had surgery to remove the tumor, the report will state whether margins are:

• Negative (good) - No cancer cells at the edge of the removed tissue
• Positive (concerning) - Cancer cells found at the edge, meaning some cancer may remain

4. Lymph Node Status

The report describes whether cancer was found in lymph nodes and how many nodes were involved. This is critical information for staging and treatment planning.

---

The Critical Biomarker Section

According to NCCN Guidelines, modern pathology reports MUST include testing for specific biomarkers (molecular characteristics of your cancer). This is essential because targeted therapies work best when these markers are present.

Key Biomarkers to Look For:

EGFR Mutations

• If present: Your cancer may respond well to targeted drugs called EGFR inhibitors (like osimertinib)
• If absent: Your doctor will consider other treatment options
• Why it matters: EGFR mutations are found in about 40% of adenocarcinomas and can dramatically change treatment recommendations

ALK Rearrangement

• If positive: Specialized ALK inhibitor drugs may be very effective for you
• If negative: Other treatments will be considered
• Why it matters: ALK-positive cancers represent about 3-5% of NSCLCs but respond dramatically to specific targeted therapies

ROS1 Rearrangement

• Similar to ALK - if present, specific targeted drugs are available
• Found in a smaller percentage of patients but important to identify

PD-L1 Expression

• Reported as a percentage (0%, 1-49%, 50% or higher)
• What it means: Higher PD-L1 levels suggest your immune system might respond well to immunotherapy drugs (checkpoint inhibitors like pembrolizumab)
• Important note: According to NCCN Guidelines, if you have a driver mutation like EGFR, targeted therapy typically takes priority over immunotherapy, even if PD-L1 is high

KRAS Mutations

• Found in about 25-30% of adenocarcinomas
• May indicate eligibility for newer targeted therapies
• Your doctor will discuss what this means for your specific situation

---

How to Read Your Report: A Step-by-Step Approach

Step 1: Find the Diagnosis Section Look for a clear statement like: "Diagnosis: Adenocarcinoma of the lung, invasive type"

Step 2: Check the Biomarker Results Look for a section labeled "Molecular Testing," "Biomarker Panel," or "Immunohistochemistry Results"

• Write down each test name and the result (positive, negative, or percentage)

Step 3: Note the Staging Information Look for tumor size, invasion depth, and lymph node involvement

• These feed into your TNM stage (T=tumor size, N=node involvement, M=metastasis)

Step 4: Identify Any Special Features Some reports mention:

• Differentiation level (well-differentiated, moderately differentiated, poorly differentiated)
• Specific growth patterns
• Necrosis (dead tissue within the tumor)

---

Important Questions to Ask Your Oncologist

Once you've reviewed your report, bring it to your next appointment and ask:

1. "Based on my specific biomarker results, what treatment options are most appropriate for me?"

   • This ensures your doctor is using your molecular findings to guide therapy

2. "Are there any biomarkers that weren't tested that I should consider testing for?"

   • Sometimes additional testing becomes relevant based on your specific situation

3. "What do my biomarker results tell us about how my cancer might respond to different treatments?"

   • This helps you understand the "why" behind treatment recommendations

4. "If I progress on my first treatment, what biomarkers should we retest?"

   • According to NCCN Guidelines, retesting after progression can reveal resistance mechanisms and guide next steps

5. "Can you explain what my PD-L1 percentage means for my treatment plan?"

   • This is especially important if you have conflicting biomarkers (like EGFR mutation + high PD-L1)

---

What You Might Not Understand: Common Confusing Terms

| Term | What It Means | |------|---------------| | Invasive | Cancer has grown beyond the surface layer into deeper tissue | | In situ | Cancer is only in the surface layer (early stage) | | Differentiation | How much the cancer cells look like normal lung cells (well-differentiated = more normal-looking) | | Necrosis | Areas of dead tissue within the tumor | | Lymphovascular invasion | Cancer cells found in blood vessels or lymph vessels | | Positive margin | Cancer cells at the edge of removed tissue | | Subclonal | A smaller population of cancer cells with different mutations than the main tumor |

---

Why Tissue Preservation Matters

According to NCCN Guidelines, your pathologist should preserve tissue specifically for molecular testing. This is important because:

• If you progress on your first treatment, doctors may need to retest your tumor
• New biomarkers and treatments are constantly being discovered
• Having preserved tissue allows for additional testing without another biopsy

If your report doesn't mention biomarker testing, ask your oncologist whether testing was done and, if not, whether it should be.

---

Bringing It All Together

Your pathology report is a roadmap for your treatment. The histologic type tells your doctor what kind of cancer you have. The biomarkers tell your doctor which treatments are most likely to work. The staging information tells your doctor how advanced it is.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.